← Back to headlines
Neurocrine to acquire Soleno Therapeutics for $2.9B to gain Prader-Willi drug
Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a $2.9 billion deal, primarily to obtain a drug for Prader-Willi syndrome.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
